COMPARE · Reviewed July 29, 2026
AMTM vs DLB
Verdict: Side-by-side breakdown using the Bull Rankings model. AMTM scored 72.0, DLB scored 72.0 — tied at the top.
Compare another set
AMTM
Amentum Holdings, Inc.
72
$21.80 · $5.3B
fundamentals as of
Score gap
0.0
Tied
DLB
Dolby Laboratories, Inc.
72
$52.54 · $5.0B
fundamentals as of
The model, pillar by pillar (0–100 each)
AMTM
stronger →← stronger
DLB
43
Qualityreturns · margins · balance sheet
73
100
Growthrevenue & earnings expansion
65
91
Valuevaluation vs sector peers
79
AMTM is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AMTM
DLB
$439mC
FCF
$258mC
+26.1%A-
Rev
+5.9%C+
0.83B
D/E
0.02A
36.3xC+
P/E
20.8xB+
0.51A-
PEG
1.29B
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
AMTM
DLB
36% below
Price vs fair valuelower is cheaper
3% above
~-2%/yr
Growth the price implies10-yr FCF · lower = less priced in
~6%/yr
+35%
1-yr DCF upside
-7%
+56%
5-yr DCF upside
-3%
+93%
10-yr DCF upside
+3%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AMTM
Why this score
- Short track record
DLB
Why this score
- Raising its dividend
The companies
AMTMAmentum Holdings, Inc.
Why now
Specialty Business Services · market cap $5.3b. Down 43% from 52-week high of $38.11 — deep drawdown territory. Revenue growing +26% — in hypergrowth territory. PEG 0.51 — paying under fair value for the growth rate. 12 sell-side analysts rate this a Buy with a mean 1-yr target of $31.75 (implying +46% upside).
Moat
Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Down 43% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Net margin 1.0% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
DLBDolby Laboratories, Inc.
Why now
Specialty Business Services · market cap $5.0b. Down 31% from 52-week high of $76.69 — deep drawdown territory. 3 sell-side analysts rate this a Buy with a mean 1-yr target of $78.33 (implying +49% upside).
Moat
Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 106% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 31% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.